Loading clinical trials...
Loading clinical trials...
The study team's central hypothesis is that the Parkland Diabetes Detection Program (PDDP) screening invitations targeted by race/ethnicity with culturally concordant messaging and tailored by glycemic risk (known PDM vs. unknown glycemic state) plus phone-based navigation of non-responders will be more effective at closing screening gaps than PDDP generic screening invitations and usual care, opportunistic screening alone.
The research team will conduct a pragmatic, split cluster randomized controlled trial (clinic=cluster; patient randomization) in 12 community-based primary care clinics in an integrated safety net health system serving a high-risk, racially/ethnically diverse population.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Parkland Health
Dallas, Texas, United States
Start Date
March 5, 2024
Primary Completion Date
December 1, 2026
Completion Date
December 30, 2028
Last Updated
April 10, 2025
500,000
ESTIMATED participants
Parkland Diabetes Detection Program (PDDP) Screening Invitation
BEHAVIORAL
Lead Sponsor
University of Texas Southwestern Medical Center
Collaborators
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062